Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study

被引：0
|
作者：
Hubert G Nüßlein
Rieke Alten
Mauro Galeazzi
Hanns-Martin Lorenz
Dimitrios Boumpas
Michael T Nurmohamed
William G Bensen
Gerd R Burmester
Hans-Hartmut Peter
Franz Rainer
Karel Pavelka
Melanie Chartier
Coralie Poncet
Christiane Rauch
Manuela Le Bars
机构：
[1] University of Erlangen-Nuremberg,Schlosspark
[2] University Medicine,Klinik
[3] University of Siena,Institute of Rheumatology and Clinic of Rheumatology
[4] University Hospital Heidelberg,undefined
[5] University of Crete,undefined
[6] VU University Medical Center/Jan van Breemen Research Institute,undefined
[7] St. Joseph’s Hospital/McMaster University,undefined
[8] Charité-Universitätsmedizin Berlin,undefined
[9] University Medical Center Freiburg,undefined
[10] Hospital Barmherzige Brueder,undefined
[11] Charles University,undefined
[12] Chiltern International,undefined
[13] Docs International,undefined
[14] Bristol-Myers Squibb,undefined
[15] Bristol-Myers Squibb,undefined
来源：
BMC Musculoskeletal Disorders | / 15卷
关键词：
Rheumatoid arthritis; Biological agents; Abatacept; Effectiveness; Safety; Registries;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study
    Ashina, Messoud
    Mitsikostas, Dimos D.
    Amin, Faisal Mohammad
    Kokturk, Pinar
    Schankin, Christoph J.
    Sahin, Gurdal
    Pozo-Rosich, Patricia
    Dorman, Paul J.
    Nezadal, Tomas
    Poole, Anne Christine
    Martins, Isabel Pavao
    Sumelahti, Marja-Liisa
    Campos, Verena Ramirez
    Ahn, Andrew H.
    Lyras, Leonidas
    Tassorelli, Cristina
    [J]. CEPHALALGIA, 2023, 43 (11)
  • [22] PREDICTORS PF REMISSION IN THE TREATMENT OF DEPRESSION IN THE MIDDLE EAST: REAL-WORLD EVIDENCE FROM A 6-MONTH PROSPECTIVE OBSERVATIONAL STUDY
    Novick, D.
    Hong, Jihyung J.
    Montgomery, W.
    Duenas, H.
    Elfatarany, G.
    Haro, J. M.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A454 - A454
  • [23] THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE & LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): 6-MONTH ANALYSIS RESULTS
    Giorgino, F.
    Guerci, B.
    Garcia-Perez, L. E.
    Boye, K.
    Aigner, U.
    Heitmann, E.
    Federici, Orsini M.
    Zimner-Rapuch, S.
    Rosilio, M.
    Norrbacka, K.
    Sapin, H.
    [J]. VALUE IN HEALTH, 2020, 23 : S506 - S506
  • [24] Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study
    Nuesslein, H. G.
    Alten, R.
    Galeazzi, M.
    Lorenz, H. -M.
    Nurmohamed, M. T.
    Bensen, W. G.
    Burmester, G. R.
    Peter, H. -H.
    Peichl, P.
    Pavelka, K.
    Chartier, M.
    Poncet, C.
    Rauch, C.
    Le Bars, M.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (03) : 489 - 499
  • [25] Effectiveness of Upadacitinib in Patients with Rheumatoid Arthritis in Canadian Real-World Practice: Interim Results from the CLOSE-UP Post-Marketing Observational Study
    Haaland, Derek
    Chan, Jonathan
    Lisnevskaia, Larissa
    Chow, Andrew
    Girard, Tanya
    Fournier, Pierre-Andre
    Bessette, Louis
    [J]. ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 578 - 581
  • [26] Effectiveness of Upadacitinib in Patients With Rheumatoid Arthritis in Canadian Real-World Practice: Interim Results From the CLOSE-UP Post-Marketing Observational Study
    Haaland, Derek
    Chan, Jonathan
    Lisnevskaia, Larissa
    Chow, Andrew
    Girard, Tanya
    Fournier, Pierre-Andre
    Bessette, Louis
    [J]. JOURNAL OF RHEUMATOLOGY, 2023, 50 (07) : 83 - 83
  • [27] The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis
    Rieke Alten
    Gerd R. Burmester
    Marco Matucci-Cerinic
    Jean-Hugues Salmon
    Pedro Lopez-Romero
    Walid Fakhouri
    Inmaculada de la Torre
    Liliana Zaremba-Pechmann
    Thorsten Holzkämper
    Bruno Fautrel
    [J]. Rheumatology and Therapy, 2023, 10 : 73 - 93
  • [28] The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis
    Alten, Rieke
    Burmester, Gerd R.
    Matucci-Cerinic, Marco
    Salmon, Jean-Hugues
    Lopez-Romero, Pedro
    Fakhouri, Walid
    de la Torre, Inmaculada
    Zaremba-Pechmann, Liliana
    Holzkaemper, Thorsten
    Fautrel, Bruno
    [J]. RHEUMATOLOGY AND THERAPY, 2023, 10 (01) : 73 - 93
  • [29] Interim 2-Year Analysis from SERENA: A Real-World Study in Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Secukinumab
    Uta Kiltz
    Petros P. Sfikakis
    Karl Gaffney
    Andreas Bounas
    Nicola Gullick
    Eric Lespessailles
    Jan Brandt-Juergens
    Rasho Rashkov
    Barbara Schulz
    Effie Pournara
    Piotr Jagiello
    [J]. Rheumatology and Therapy, 2022, 9 : 1129 - 1142
  • [30] Interim 2-Year Analysis from SERENA: A Real-World Study in Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Secukinumab
    Kiltz, Uta
    Sfikakis, Petros P.
    Gaffney, Karl
    Bounas, Andreas
    Gullick, Nicola
    Lespessailles, Eric
    Brandt-Juergens, Jan
    Rashkov, Rasho
    Schulz, Barbara
    Pournara, Effie
    Jagiello, Piotr
    [J]. RHEUMATOLOGY AND THERAPY, 2022, 9 (04) : 1129 - 1142
12345